CONCORDBIOPharmaceuticals
Concord Biotech Ltd — Cash Flow Statement
₹1018.40
-2.34%
Concord Biotech Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | 133.34 Cr | 179.78 Cr | 100.92 Cr | 51.97 Cr | — |
| Repayment Of Debt | -5.86 Cr | -25.01 Cr | -25.00 Cr | -25.00 Cr | — |
| Capital Expenditure | -111.17 Cr | -85.69 Cr | -145.08 Cr | -155.50 Cr | — |
| End Cash Position | 0.90 Cr | 15.14 Cr | 3.50 Cr | 0.67 Cr | — |
| Beginning Cash Position | 15.14 Cr | 3.50 Cr | 0.67 Cr | 5.14 Cr | — |
| Changes In Cash | -14.24 Cr | 11.64 Cr | 2.83 Cr | -4.48 Cr | — |
| Financing Cash Flow | -98.77 Cr | -99.21 Cr | -85.22 Cr | -100.16 Cr | — |
| Net Other Financing Charges | 0.16 Cr | 1.39 Cr | 3.24 Cr | 3.09 Cr | — |
| Interest Paid Cff | -0.63 Cr | -2.65 Cr | -3.96 Cr | -5.32 Cr | — |
| Cash Dividends Paid | -91.54 Cr | -71.45 Cr | -53.56 Cr | -70.52 Cr | — |
| Common Stock Dividend Paid | -91.54 Cr | -71.45 Cr | -53.56 Cr | — | — |
| Net Issuance Payments Of Debt | -5.86 Cr | -25.01 Cr | -29.34 Cr | -25.76 Cr | — |
| Net Long Term Debt Issuance | -5.86 Cr | -25.01 Cr | -25.00 Cr | -25.00 Cr | — |
| Long Term Debt Payments | -5.86 Cr | -25.01 Cr | -25.00 Cr | -25.00 Cr | — |
| Investing Cash Flow | -159.99 Cr | -154.61 Cr | -157.95 Cr | -111.79 Cr | — |
| Interest Received Cfi | 2.99 Cr | 2.77 Cr | 5.58 Cr | 4.14 Cr | — |
| Net Investment Purchase And Sale | -52.01 Cr | -71.87 Cr | -18.48 Cr | 39.52 Cr | — |
| Sale Of Investment | 833.05 Cr | 766.23 Cr | 624.62 Cr | 561.44 Cr | — |
| Purchase Of Investment | -885.06 Cr | -838.10 Cr | -643.10 Cr | -521.91 Cr | — |
| Net PPE Purchase And Sale | -110.97 Cr | -85.51 Cr | -145.06 Cr | -155.45 Cr | — |
| Sale Of PPE | 0.20 Cr | 0.18 Cr | 0.03 Cr | 0.06 Cr | — |
| Purchase Of PPE | -111.17 Cr | -85.69 Cr | -145.08 Cr | -155.50 Cr | — |
| Operating Cash Flow | 244.52 Cr | 265.47 Cr | 246.00 Cr | 207.47 Cr | — |
| Taxes Refund Paid | -109.42 Cr | -103.35 Cr | -70.28 Cr | -60.78 Cr | — |
| Change In Working Capital | -170.76 Cr | -81.18 Cr | -52.29 Cr | -22.05 Cr | — |
| Change In Other Current Liabilities | 21.66 Cr | 6.13 Cr | -9.21 Cr | 11.41 Cr | — |
| Change In Other Current Assets | -13.94 Cr | 0.33 Cr | -19.13 Cr | 24.17 Cr | — |
| Change In Payable | 22.09 Cr | -11.29 Cr | 9.88 Cr | 36.53 Cr | — |
| Change In Inventory | -31.71 Cr | 4.36 Cr | -17.23 Cr | -41.51 Cr | — |
| Change In Receivables | -170.79 Cr | -78.66 Cr | -43.10 Cr | -52.77 Cr | — |
| Other Non Cash Items | -1.28 Cr | -1.57 Cr | -2.19 Cr | -2.24 Cr | — |
| Provisionand Write Offof Assets | -0.95 Cr | 0.63 Cr | -1.66 Cr | 1.92 Cr | — |
| Depreciation And Amortization | 54.37 Cr | 53.59 Cr | 54.03 Cr | 50.05 Cr | — |
| Depreciation | 54.37 Cr | 53.59 Cr | 50.65 Cr | 46.66 Cr | — |
| Gain Loss On Investment Securities | -22.26 Cr | -14.06 Cr | -3.72 Cr | -5.23 Cr | — |
| Net Foreign Currency Exchange Gain Loss | -1.29 Cr | 2.23 Cr | 1.95 Cr | -1.83 Cr | — |
| Gain Loss On Sale Of PPE | 0.22 Cr | -0.01 Cr | 0.09 Cr | 0.03 Cr | — |
| Net Income From Continuing Operations | 494.55 Cr | 412.56 Cr | 322.01 Cr | 237.52 Cr | — |
| Net Short Term Debt Issuance | — | 0.00 | -4.34 Cr | -0.76 Cr | 5.10 Cr |
| Amortization Cash Flow | — | 0.34 Cr | 3.38 Cr | 3.40 Cr | 3.26 Cr |
| Issuance Of Debt | — | — | 0.00 | 0.00 | 51.97 Cr |
| Long Term Debt Issuance | — | — | 0.00 | 0.00 | 51.97 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Concord Biotech Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.